Modern veterinary safety case management is no longer just an operational pharmacovigilance activity—it is a business-critical function that directly affects regulatory compliance, product safety, and market confidence. As veterinary pharmaceutical companies expand into new markets, manage growing product portfolios, and navigate increasingly complex regulatory requirements, the volume and complexity of adverse event reports continue to rise. Marketing authorisation holders are expected to maintain robust pharmacovigilance systems capable of collecting, assessing, documenting, and reporting veterinary safety cases throughout the product lifecycle.
Beyond regulatory obligations, inefficient veterinary safety case management can significantly increase operational costs, delay regulatory decision-making, reduce data quality, and place unnecessary pressure on internal pharmacovigilance teams. As product portfolios expand and reporting volumes continue to grow, fragmented case management processes become increasingly difficult to scale, making it harder for companies to maintain both compliance and operational efficiency.
The challenge is that many organisations still rely on fragmented processes, limited internal resources, or multiple service providers to manage safety cases. This often leads to inconsistent data quality, reporting delays, increased compliance risks, and unnecessary pressure on internal pharmacovigilance teams. When every case has the potential to impact patient safety, regulatory inspections, and business reputation, inefficient case management quickly becomes an expensive problem rather than simply an operational inconvenience.
For this reason, more companies are actively searching for end-to-end vet safety case management vendors that can provide complete, scalable, and inspection-ready support across the entire case lifecycle. However, not all providers offer the same level of veterinary expertise, regulatory knowledge, quality oversight, or operational flexibility. Choosing the right partner requires careful evaluation of both technical capabilities and long-term strategic value.
This guide explains what pharmaceutical companies should look for when selecting a provider of veterinary safety case management, why comprehensive end-to-end services matter, and how Billev Pharma East helps companies strengthen compliance, improve operational efficiency, and build a reliable, inspection-ready veterinary pharmacovigilance operation.
What pharmaceutical companies must do to build an effective veterinary safety case management process
Building an effective veterinary safety case management process requires much more than simply processing adverse event reports. Companies must establish a structured pharmacovigilance system that ensures every safety case is handled consistently, accurately, and within regulatory timelines. Under EU veterinary pharmacovigilance requirements, marketing authorisation holders are responsible for maintaining a documented pharmacovigilance system supported by appropriate quality management processes, qualified personnel, and reliable case management procedures.
Companies should also establish clearly defined governance, documented responsibilities, performance indicators, and regular quality reviews to verify that outsourced or internal pharmacovigilance activities continue to meet regulatory expectations. Continuous oversight is a key component of an effective pharmacovigilance system under the Veterinary Good Pharmacovigilance Practices (VGVP) in the European Union, while companies operating in Great Britain must also comply with the Veterinary Medicines Regulations and the pharmacovigilance guidance issued by the Veterinary Medicines Directorate (VMD). At Billev Pharma East, we support clients in building and maintaining compliant veterinary pharmacovigilance systems under both the EU and UK regulatory frameworks, helping them navigate evolving requirements across multiple markets.
An effective process begins with the timely intake and identification of reportable safety information from every relevant source, including healthcare professionals, animal owners, distributors, literature, digital channels, and partner organisations. Each case should then undergo validation, medical assessment, coding using appropriate veterinary terminology, quality control, and regulatory reporting where required. Companies also need robust follow-up procedures to obtain missing information and ensure each case contains sufficient data for accurate assessment. Throughout the process, every activity must be fully documented, traceable, and inspection-ready.
Beyond individual case processing, organisations should continuously monitor case quality, reporting timelines, workload, and compliance metrics. Standard operating procedures, trained pharmacovigilance personnel, quality management systems, and clear governance are essential to maintaining consistent performance as reporting volumes grow. Regular quality reviews and process improvements help minimise compliance risks while ensuring patient, user, animal, and environmental safety remain protected throughout the product lifecycle.
Companies that invest in a comprehensive veterinary safety case management process create a stronger foundation for long-term pharmacovigilance performance. Standardised workflows, clearly defined responsibilities, and continuous process monitoring improve data consistency, enable better decision-making, and help organisations respond more effectively as reporting volumes and product portfolios continue to grow.
Why Billev Pharma East is the right partner for your veterinary safety case management
Choosing the right partner for veterinary safety case management is about more than outsourcing case processing—it’s about strengthening your entire veterinary pharmacovigilance system. As regulatory expectations continue to evolve under Regulation (EU) 2019/6 and the Veterinary Good Pharmacovigilance Practices (VGVP) andThe Veterinary Medicines (Amendment etc.) Regulations 2024 (UK Regulations) , companies need a partner that combines scientific expertise, regulatory knowledge, and operational excellence to ensure long-term compliance and patient safety.
Working with one integrated partner allows companies to replace fragmented vendor models with a single, coordinated pharmacovigilance framework. Instead of managing multiple suppliers, communication channels, and quality systems, organisations benefit from one governance structure, harmonised processes, and consistent service delivery across the entire veterinary pharmacovigilance lifecycle. By bringing these capabilities together under one roof, we help veterinary pharmaceutical companies build efficient, compliant, and sustainable pharmacovigilance operations rather than simply managing day-to-day workloads.
Whether you require support for a growing product portfolio, additional operational capacity, or a fully outsourced veterinary pharmacovigilance function, our experts become an extension of your team. We tailor our services to your organisation’s needs, helping you improve operational resilience, accelerate onboarding of new products, scale pharmacovigilance activities efficiently, and maintain consistent service quality as your organisation grows. This enables your internal teams to focus on product development, regulatory strategy, and commercial growth while our specialists manage the day-to-day complexity of veterinary pharmacovigilance.
If you are looking for a trusted, long-term partner to optimise your veterinary safety case management, Billev Pharma East delivers the expertise, regulatory insight, and end-to-end support needed to protect animal health, maintain compliance, and help your business grow with confidence.
What should you evaluate when selecting end-to-end vet safety case management vendors?
Selecting a provider for veterinary safety case management is a strategic decision that goes far beyond comparing service costs or processing capacity. Companies should assess not only technical capabilities but also governance models, communication practices, scalability, performance monitoring, and the provider’s ability to support future business growth.
The right partner should be able to support your entire pharmacovigilance system, ensuring every safety case is managed in accordance with applicable regulations, quality standards, and inspection expectations. EU Veterinary Good Pharmacovigilance Practices (VGVP) place significant emphasis on well-defined pharmacovigilance systems, quality management, documented procedures, and continuous compliance—not simply on individual case processing.
One of the first questions companies should ask is whether the provider truly delivers end-to-end services. This includes case intake from multiple reporting channels, case validation, medical assessment, coding using veterinary terminology, follow-up activities, quality control, regulatory submissions, reconciliation, compliance monitoring, and complete audit documentation. Working with multiple providers for different parts of the process often creates communication gaps, inconsistent data quality, and additional compliance risks.
Veterinary expertise should also be a key evaluation criterion. Veterinary pharmacovigilance differs significantly from human pharmacovigilance, requiring knowledge of species-specific safety considerations, veterinary regulatory requirements, and the unique reporting obligations that apply to animal health products. A provider should have experienced veterinary pharmacovigilance professionals, established quality management systems, documented standard operating procedures, and the ability to scale resources as reporting volumes increase or business needs evolve.
Finally, companies should evaluate whether a provider can become a long-term strategic partner rather than simply a transactional service supplier. The strongest providers support continuous process improvement, inspection readiness, quality oversight, and operational scalability while integrating seamlessly with existing pharmacovigilance systems. Choosing a partner with these capabilities helps strengthen veterinary safety case management, reduce operational risk, and build a more resilient pharmacovigilance function that supports long-term regulatory compliance and business growth.
Why more companies are choosing end-to-end veterinary safety case management
As veterinary pharmacovigilance requirements become more demanding, many pharmaceutical companies are moving away from fragmented service models and adopting end-to-end veterinary safety case management. Instead of coordinating multiple vendors for case processing, quality review, regulatory reporting, and pharmacovigilance oversight, organisations increasingly recognise the value of working with a single strategic partner that can manage the entire safety case lifecycle. This approach simplifies governance, improves communication, and creates greater consistency across pharmacovigilance activities while supporting compliance with Veterinary Good Pharmacovigilance Practices (VGVP).
Another important advantage of end-to-end veterinary safety case management is greater operational visibility. With one partner managing the complete case lifecycle, companies gain access to harmonised performance metrics, centralised reporting, consistent quality indicators, and clearer oversight of pharmacovigilance activities. This enables faster decision-making, easier resource planning, and better strategic control across global operations.
Another key driver is scalability. Veterinary pharmaceutical companies often experience fluctuating reporting volumes due to product launches, market expansion, acquisitions, or changing regulatory requirements. End-to-end veterinary safety case management allows organisations to rapidly scale resources without investing in additional internal infrastructure or specialised personnel. At the same time, companies retain oversight of their pharmacovigilance system while benefiting from experienced experts, established quality processes, and proven regulatory workflows.
By consolidating pharmacovigilance activities within one experienced partner, our clients simplify vendor management, gain greater operational visibility, and create a more agile pharmacovigilance function that can adapt as regulatory and business needs evolve.
Why choosing the right veterinary safety case management partner matters
Selecting a partner for veterinary safety case management is not simply an operational outsourcing decision—it is a strategic investment in the long-term performance of your pharmacovigilance system. Regulatory authorities expect marketing authorisation holders to maintain complete oversight of their pharmacovigilance activities, even when specific tasks are delegated to an external provider. This means your partner must not only process safety cases accurately but also support quality management, documentation, regulatory compliance, inspection readiness, and continuous oversight across the entire pharmacovigilance system.
An effective partner should contribute to more than regulatory compliance. High-quality veterinary safety case management enables organisations to identify emerging safety signals earlier, maintain a favourable benefit-risk balance, improve data quality, and make informed regulatory and business decisions throughout the lifecycle of veterinary medicinal products. As veterinary pharmacovigilance continues to evolve, companies increasingly benefit from partners who combine scientific expertise with scalable operational processes and a thorough understanding of global regulatory expectations.
The most successful partnerships are built on transparency, clearly defined responsibilities, measurable service quality, proactive communication, and continuous improvement. A partner should provide strategic guidance alongside operational support, helping organisations strengthen their pharmacovigilance capabilities as regulatory expectations continue to evolve.
At Billev Pharma East, we combine strategic consulting with day-to-day operational support, enabling our clients to strengthen their pharmacovigilance capabilities while maintaining flexibility as their organisations grow.
Future-proof your veterinary safety case management
As veterinary pharmacovigilance continues to evolve, veterinary safety case management has become a strategic capability rather than a standalone operational activity. Future-ready pharmacovigilance systems increasingly rely on integrated digital workflows, structured signal management, high-quality safety data, and continuous quality improvement to support faster regulatory decision-making and proactive risk management throughout the product lifecycle. A well-managed pharmacovigilance system not only supports compliance but also strengthens decision-making, operational resilience, and long-term business performance.
The future of veterinary safety case management will be defined by greater integration, stronger data quality, and increasingly proactive pharmacovigilance. As regulatory expectations evolve and veterinary product portfolios become more complex, organisations will need pharmacovigilance systems that are not only compliant but also flexible enough to support faster decision-making, continuous improvement, and sustainable business growth. Companies that invest in modern, scalable safety processes today will be better prepared to respond to future regulatory changes and maintain confidence across global markets.
Whether you are establishing a new veterinary pharmacovigilance system or looking to optimise an existing one, Billev Pharma East provides tailored end-to-end solutions that help you build a scalable, future-ready veterinary safety case management framework aligned with your business objectives.
Frequently asked questions
What is veterinary safety case management?
Veterinary safety case management is the process of collecting, validating, assessing, documenting, and reporting adverse events and other reportable safety information related to veterinary medicinal products. It forms a core part of veterinary pharmacovigilance and helps marketing authorisation holders maintain compliance while protecting animal, user, and environmental safety.
What is included in veterinary safety case management?
A comprehensive veterinary safety case management service typically includes case intake, validation, medical assessment, veterinary coding, follow-up activities, quality control, regulatory submissions, documentation, and ongoing compliance monitoring. Many organisations also integrate safety case management with broader pharmacovigilance activities such as signal management and quality oversight.
Why are companies choosing end-to-end vet safety case management vendors?
Many companies choose end-to-end vet safety case management vendors to simplify pharmacovigilance operations, improve process consistency, reduce the complexity of managing multiple service providers, and gain access to specialised veterinary expertise. An integrated service model also supports better governance, scalability, and long-term regulatory compliance.
Can veterinary safety case management be outsourced?
Yes. Companies can outsource veterinary safety case management as well as a wide range of veterinary pharmacovigilance and regulatory activities, including QPPV services, PSMF management, signal management, literature monitoring, regulatory reporting, and quality management support. Outsourcing enables organisations to access specialised expertise, improve scalability, and maintain efficient pharmacovigilance operations. However, while operational and regulatory tasks may be delegated to a qualified service provider, the ultimate legal responsibility for fulfilling pharmacovigilance obligations always remains with the marketing authorisation holder (MAH). For this reason, organisations should select a partner with established quality systems, proven veterinary pharmacovigilance expertise, and robust governance processes.
Sources: 1 – European Medicines Agency. (2025). Pharmacovigilance (veterinary medicines), 2 – European Medicines Agency. (2025). Veterinary Good Pharmacovigilance Practices (VGVP), 3 – European Medicines Agency. (2022). Guideline on Veterinary Good Pharmacovigilance Practices (VGVP): Pharmacovigilance systems, quality management systems and pharmacovigilance system master file, 4 – European Medicines Agency. (2022). Guideline on Veterinary Good Pharmacovigilance Practices (VGVP): Collection and recording of suspected adverse events for veterinary medicinal products, 5 – European Medicines Agency. (2022). Guideline on Veterinary Good Pharmacovigilance Practices (VGVP): Signal management, 6 – European Medicines Agency. (2022). Guideline on Veterinary Good Pharmacovigilance Practices (VGVP): Controls and pharmacovigilance inspections.
Image credits:
In-article images: Pexels
In-article images: Pexels
Hero image: Pexels